Press release: ProTrans stem cells approved for clinical trials in COVID-19 patients
Corona virus ProTrans for the treatment of patients with COVID-19 WED, OCT 21, 2020 17:00 CET NextCell Pharma AB ("NextCell") today announces that the application for clinical trial of COVID-19...
Allogeneic cell therapy has again shown an effect in type 1 diabetes
Type 1 diabetes ProTrans™, a drug candidate consisting of umbilical cord stem cells “Our vision is to improve treatment options for thousands, maybe millions of patients and reducing healthcare costs...
Rigshospitalet performs treatment with stem cells from the umbilical cord
RIGSHOSPITALET Transplantation with stem cells from the umbilical cord is a treatment option for patients for whom we cannot find a suitable bone marrow donor. In Denmark, approx. 20% of...
Press release: ProTrans shows significant effect in Diabetes
Cellaviva's mother company NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved...
Covid-19 study shows the positive effect of treatment with stem cells
The first study to test the effect of mesenchymal stem cells in the treatment of COVID-19 has now been published.
Covid-19 patients are treated with stem cells
Covid-19 patients are treated with stem cells A study published in Aging and Disease* shows the effect of treatment with mesenchymal stem cells, MSC (the same type of stem cells...